Renalytix Plc Regulatory News (RENX)

Renalytix plc

("Renalytix" or the "Company")

Directorate Change

LONDON and SALT LAKE CITY - December 8, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dr Chirag Parikh has stepped down from his role as independent Non-Executive Director of Renalytix with immediate effect.

The Company will seek to recruit a new independent Non-Executive Director and will provide an update in due course.

The Ordinary Resolution to re-appoint Dr Parikh to the Board of Directors will be withdrawn for the Annual General Meeting to be held on 15 December 2023.

For further information, please contact:

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis? for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.